Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

  • Etude concernée: IFCT-1802
  • Auteurs / Authors: V. Gounant, L. Greillier, C. Mascaux, F. Pinquie, D. Carmier, L. Moreau, B. Roch, D. Debieuvre, X. Dhalluin, E. Giroux-leprieur, E. Berton, A. Rabeau, J. Raimbourg, A. Dixmier, C. Naltet, A. Khalil, L. Ezzeddine, A. Langlais, F. Morin, M. Duruisseaux
  • Journal / Conference: ESMO
  • Année / Year: 2024
  • PMID: Poster
  • Lien vers la publication: images/IFCT-1802_ESMO-2024_v1.0_20240910_IFCT.pdf